|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 10/25/19 Nano Mobile Healthcare, Inc. 8-K:5 10/25/19 1:19K Securex Filings/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 14K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 25, 2019
NANO MOBILE HEALTHCARE, INC.
(Exact Name of Registrant as Specified in its Charter)
| Delaware (State or other jurisdiction of incorporation) |
000-55155 (Commission File Number) |
98-0659770 (I.R.S. Employer Identification No.) |
One Boston Place Suite
2600
Boston, MA 02108
(Address of Principal Executive Offices and Zip Code)
Registrant’s telephone number, including area code: (617) 336-7001
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
| Common Stock, par value of $0.00001 | VNTH | OTCMKTS |
| C: |
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.
On October 25, 2019 Joseph C. Peters resigned as a member of the Board of Directors (the “Board”) of Nano Mobile Healthcare (the “Company”), effective as of the date of such resignation. Mr. Peters also resigned as Chairman of the Board and Chief Executive Officer of the Company effective as of such date. Mr. Peters’ resignation was not the result of any dispute or disagreement with the Company or the Company’s Board of Directors on any matter relating to the operations, policies or practices of the Company.
Robert Chicoski has been appointed the interim CEO for the Company effective October 25, 2019.
C:
| 2 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NANO MOBILE HEALTHCARE, INC.
| Date: October 25, 2019 | By: /s/ Robert Chicoski | |
| Name: | Robert Chicoski | |
| Title: | Chief Financial Officer and Interim CEO | |
3
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on / For Period end: | 10/25/19 | None on these Dates | ||
| List all Filings | ||||